Formycon Raises Fresh Capital To Drive Biosimilar Development
Funding For COVID-19 Also Received
German biosimilars firm Formycon has raised tens of millions of euros through an issue of new shares, with the cash earmarked for its burgeoning pipeline of wholly-owned biosimilars, including a Lucentis (ranibizumab) candidate being developed with Coherus.
You may also be interested in...
H2 Pharma, which specializes in both generic and OTC liquid formulations, is looking to climb to the next level after receiving an equity investment from Ardian.
London-listed Hikma has signed a second partnership agreement with Arecor, proposing to co-develop a 505(b)(2) hybrid injectable product for the US market.
Zentiva has struck a new partnership to expand its already significant operations in Europe, this time in Greece with local firm Lavipharm.